Clinical trials have shown most people respond to Keytruda within 2-4 months of starting treatment (seeHow long does it take for Keytruda to work?). Types of cancer treated with Keytruda Keytruda is FDA-approved to treat numerous cancers, including certain types of: ...
Health care professionals may find information about FDA-approved indications for KEYTRUDA® (pembrolizumab) along with KEYNOTE clinical trials and treatment guidelines.
double-blind, Phase 3 trial (ClinicalTrials.gov, NCT03725059) that is fully accrued, evaluating KEYTRUDA in combination with chemotherapy as neoadjuvant treatment, followed by adjuvant treatment with KEYTRUDA plus en...
Related:FDA approval history and clinical trials for Keytruda Keytruda is used to treat cancers such as: melanoma, squamous cell carcinoma, or Merkel cell carcinoma (types of serious skin cancer) lung cancer, Non-Small Cell Lung Cancer (NSCLC) ...
KEYTRUDA is approved for use in combination with chemotherapy before surgery when you have early-stage NSCLC, which can be removed by surgery, and then continued alone after surgery to help prevent your lung cancer from coming back. Results from a clinical trialSee if KEYTRUDA for early-stage ...
Head and neck cancer Leukemias, lymphomas, and other hematologic cancers Melanoma and other skin cancers Respiratory and thoracic cancers Solid tumors Bladder, kidney, and other urologic cancers Breast cancer Colorectal and other GI cancers Gynecologic cancers Head and neck cancer Leukemias...
“KEYTRUDA is the first immunotherapy to show positive results for event-free survival in patients with high-risk early-stage TNBC, a particularly aggressive form of breast cancer,” said Roy Baynes, MD, senior vice president and head of global clinical development at Merck Research ...
(HCC), metastatic biliary tract cancer (BTC), Merkel cell carcinoma (MCC), renal cell carcinoma (RCC), endometrial carcinoma, metastatic tumor mutational burden-high (TMB-H) cancer, cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC, triple-negative breast cancer (TNBC), and ...
The diagnosis of triple-negative breast cancer is confirmed by the cancer cells testing negative forallof the following receptors: Human epidermal growth factor receptor 2 (HER-2);and Estrogen;and Progesterone;and Tumor must express PD-L1;and ...
instability-high or mismatch repair deficient colorectal cancer; esophageal cancer; cervical cancer; hepatocellular carcinoma; Merkel cell carcinoma; renal cell carcinoma; endometrial carcinoma; tumor mutational burden-high cancer; cutaneous squamous cell carcinoma; and triple-negative breast cancer. ...